Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of ESSA Pharma's Masofaniten?
Masofaniten is a small molecule commercialized by ESSA Pharma, with a leading Phase I program in Castration-Resistant Prostate Cancer (CRPC)....